Indoco Remedies Ltd
NSE:INDOCO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (16.6), the stock would be worth ₹127.71 (40% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 27.5 | ₹211.6 |
0%
|
| 3-Year Average | 16.6 | ₹127.71 |
-40%
|
| 5-Year Average | 15.4 | ₹118.02 |
-44%
|
| Industry Average | 21.2 | ₹162.64 |
-23%
|
| Country Average | 17.7 | ₹135.73 |
-36%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
₹23.4B
|
/ |
Jan 2026
₹880m
|
= |
|
|
₹23.4B
|
/ |
Mar 2026
₹1.2B
|
= |
|
|
₹23.4B
|
/ |
Mar 2027
₹3B
|
= |
|
|
₹23.4B
|
/ |
Mar 2028
₹3.6B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Indoco Remedies Ltd
NSE:INDOCO
|
19.5B INR | 27.5 | -17.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
871.6B USD | 28.5 | 42.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.1B USD | 15 | 21.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.6 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.4B GBP | 16.6 | 30 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296.9B USD | 10.1 | 16.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.4B CHF | 12.8 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 7.9 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.5B USD | 7.6 | 19.8 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
89.3B GBP | 8.4 | 15.6 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 11.9 |
| Median | 17.7 |
| 70th Percentile | 27.8 |
| Max | 47 834.4 |
Other Multiples
Indoco Remedies Ltd
Glance View
Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-01-07. The firm is an integrated, research-oriented pharma company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm's geographical segments include India and Outside India. The firm has nine domestic marketing divisions with a brand portfolio in various therapeutic segments, including Gastrointestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management and Gyneacology. The Company’s brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cal-Aid, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM and Methycal.
